Cargando…
Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to 'on-demand' PDE5 inhibitors. In addition, the lack of spontaneity and natural...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382685/ https://www.ncbi.nlm.nih.gov/pubmed/22741044 http://dx.doi.org/10.4111/kju.2012.53.6.377 |
_version_ | 1782236526773534720 |
---|---|
author | Sung, Hyun Hwan Lee, Sung Won |
author_facet | Sung, Hyun Hwan Lee, Sung Won |
author_sort | Sung, Hyun Hwan |
collection | PubMed |
description | Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to 'on-demand' PDE5 inhibitors. In addition, the lack of spontaneity and naturalness of the on-demand regimen could be a reason for decreased compliance with PDE5 inhibitors. Recently, tadalafil and udenafil were approved for low-dose daily administration for the treatment of ED. Since the introduction of the concept of daily administration of PDE5 inhibitors, several reports have supported the potential benefits of this therapy for disease modification, improvement of the treatment response in difficult-to-treat populations, spontaneity, and safety, although further research is needed to better address these hypotheses. In this article, we reviewed the daily administration of PDE5 inhibitors in terms of pharmacokinetics, safety, efficacy, and distinct features. |
format | Online Article Text |
id | pubmed-3382685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Korean Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-33826852012-06-27 Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction Sung, Hyun Hwan Lee, Sung Won Korean J Urol Review Article Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to 'on-demand' PDE5 inhibitors. In addition, the lack of spontaneity and naturalness of the on-demand regimen could be a reason for decreased compliance with PDE5 inhibitors. Recently, tadalafil and udenafil were approved for low-dose daily administration for the treatment of ED. Since the introduction of the concept of daily administration of PDE5 inhibitors, several reports have supported the potential benefits of this therapy for disease modification, improvement of the treatment response in difficult-to-treat populations, spontaneity, and safety, although further research is needed to better address these hypotheses. In this article, we reviewed the daily administration of PDE5 inhibitors in terms of pharmacokinetics, safety, efficacy, and distinct features. The Korean Urological Association 2012-06 2012-06-19 /pmc/articles/PMC3382685/ /pubmed/22741044 http://dx.doi.org/10.4111/kju.2012.53.6.377 Text en © The Korean Urological Association, 2012 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Sung, Hyun Hwan Lee, Sung Won Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction |
title | Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction |
title_full | Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction |
title_fullStr | Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction |
title_full_unstemmed | Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction |
title_short | Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction |
title_sort | chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382685/ https://www.ncbi.nlm.nih.gov/pubmed/22741044 http://dx.doi.org/10.4111/kju.2012.53.6.377 |
work_keys_str_mv | AT sunghyunhwan chroniclowdosingofphosphodiesterasetype5inhibitorforerectiledysfunction AT leesungwon chroniclowdosingofphosphodiesterasetype5inhibitorforerectiledysfunction |